A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea

Ulcerative Colitis Clinical Trial

Official title:

Post-Marketing Surveillance (Usage Results Study) of Vedolizumab Subcutaneous Injection in Patients With Ulcerative Colitis or Crohn's Disease in South Korea

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05428345
• Other study ID #: VedolizumabSC-4003
• Status: Recruiting
• Start date: September 25, 2023
• Est. completion date: November 30, 2027

Study information

• Verified date: October 2023
• Source: Takeda
• Contact: Takeda Contact
• Phone: +1-877-825-3327
• Email: medinfoUS[@]takeda.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The main aim of the study is to observe adult participants in South Korea that are being treated with vedolizumab injected just under the skin (subcutaneous or SC) to treat ulcerative colitis (UC) or Crohn's disease (CD) who have had an in-adequate response with, lost response to, or had too many side effects in response to either conventional therapy or a Tumor Necrosis Factor-alpha (TNF-α) antagonist. This study will observe the side effects and potential benefit to UC and CD participants related to vedolizumab SC treatment with data collection from medical files. There is no treatment involved in this study, this is only an observational review of current collected data relating to adults in South Korea with UC or CD treated with vedolizumab SC.

Description:

This is a prospective, non-interventional, post-marketing study of adult participants with moderately to severely active UC or CD, who have had an inadequate response with, lost response to, or were intolerant to conventional therapy or a TNF-α antagonist. This study will evaluate the safety and effectiveness of vedolizumab SC in a routine clinical practice setting under real world condition.

This study will enroll approximately 600 participants. The data will be prospectively collected, at the centers and recorded into electronic case report forms (e-CRFs). All participants will be enrolled in a single observational group:

• Participants with UC or CD

This multi-center trial will be conducted in South Korea. The overall time for data collection in the study will be approximately 6 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: November 30, 2027
• Est. primary completion date: November 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. With moderately to severely active UC or CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-a antagonist

2. With evidence of therapeutic benefit after at least 2 vedolizumab intravenous infusions

Exclusion Criteria:

1. With hypersensitivity such as dyspnea, bronchospasm, urticaria, flushing and increased heart rate to the vedolizumab substance or to any of its excipients

2. With active severe infections such as tuberculosis, cytomegalovirus, sepsis, listeriosis and opportunistic infections such as Progressive Multifocal Leukoencephalopathy (PML)

3. For whom vedolizumab SC is contraindicated as per product label

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Crohn Disease
• Crohn's Disease
• Inflammatory Bowel Disease (IBD)
• Inflammatory Bowel Diseases
• Ulcer
• Ulcerative Colitis

Locations

Country	Name	City	State
Korea, Republic of	Donggguk University Ilsan Hospital	Goyang-si	Gyeonggi-do

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Serious Adverse Events (SAEs)		Up to Week 52
Primary	Percentage of Participants With Adverse Drug Reactions (ADRs)		Up to Week 52
Primary	Percentage of Participants With Serious Adverse Drug Reactions (SADRs)		Up to Week 52
Primary	Percentage of Participants With Adverse Events of Special Interest (AESIs)		Up to Week 52
Primary	Percentage of Participants With Unexpected Adverse Events (AEs)		Up to Week 52
Primary	Percentage of Participants With Unexpected ADRs		Up to Week 52
Secondary	Percentage of Participants With UC and CD Who Achieved Clinical Response	Clinical response:reduction of Mayo score of greater than or equal to(>=)3points and >=30 percent(%) from baseline score, with an accompanying decrease in rectal bleeding subscore >=1 point/an absolute rectal bleeding sub-score of less than or equal to(<=)1 point in UC participants;and reduction of Crohn's Disease Activity Index (CDAI) score >=70 points from baseline score in CD participants. Total Mayo score measures disease activity of UC;comprise of 4 sections: stool frequency,rectal bleeding,physician rating of disease activity,endoscopic findings. Each graded from 0-3. Total scores range from 0-12.Higher scores indicate more severity.CDAI assesses CD based on clinical signs such as number of liquid stools,abdominal pain,general wellbeing,presence of complications,opiates for diarrhea,presence of abdominal mass, hematocrit. CDAI consist of eight factors,each summed after adjustment with a weighting factor. Total score ranged from 0-600 points.Higher scores indicate more severity.	Up to Week 52
Secondary	Percentage of Participants With UC and CD Who Achieved Clinical Remission	Clinical remission is defined as: total Mayo score <=2 and no individual sub-score greater than (>) 1 point in UC participants; and CDAI score less than (<) 150 points in CD participants. Total Mayo score measures disease activity of UC; comprise of 4 sections: stool frequency, rectal bleeding, physician rating of disease activity, endoscopic findings. Each graded from 0-3. Total scores range from 0-12. Higher scores indicate more severity. CDAI assesses CD based on clinical signs such as number of liquid stools, abdominal pain, general wellbeing, presence of complications, opiates for diarrhea, presence of abdominal mass, hematocrit. CDAI consist of eight factors, each summed after adjustment with a weighting factor. Total score ranged from 0-600 points. Higher scores indicate more severity.	Up to Week 52
Secondary	Percentage of Participants With UC and CD Who Achieved Mucosal Healing	Mucosal healing is defined as: Mayo endoscopic sub-score of <=1 point in the UC participants; and Crohn's Disease Endoscopic Index of Severity (CDEIS) score <3.5 points in the CD participants. Mayo score: instrument to measure disease activity of UC; consists of 4 variables: stool frequency, rectal bleeding, physician rating of disease activity, and endoscopic findings. Each graded from 0-3. Total score range of 0-12. Higher scores indicating more severity. CDEIS comprise of 4 sections assessing endoscopic severity of CD in 5 segments: rectum; sigmoid and left colon; transverse colon; right colon; ileum in terms of: deep ulcerations, superficial ulcerations, surface involved by disease and ulcerated surface measured. The presence of ulcerate and non-ulcerated stenosis will be recorded in each segment. CDEIS score range from 0-44 with a higher score indicating greater severity of disease.	Up to Week 52

External Links

•   To obtain more information about this study, use this link.